<DOC>
	<DOCNO>NCT01218620</DOCNO>
	<brief_summary>This randomized phase I trial study side effect best dose RO4929097 treat patient advance solid tumor . RO4929097 may stop growth tumor cell block enzymes need cell growth .</brief_summary>
	<brief_title>Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate extent RO4929097 induce metabolism use 20mg dose Regimen I 50mg dose Regimen II compare Cycle 1 Day 1 Day 10 plasma pharmacokinetic parameter . SECONDARY OBJECTIVES : I . To evaluate effect strong inhibitor CYP3A4 , ketoconazole , RO4929097 plasma pharmacokinetics . II . To evaluate effect strong inducer CYP3A4 , 2D6 2C9 , rifampin RO4929097 plasma pharmacokinetics . III . To evaluate effect RO4929097 plasma pharmacokinetics CYP450 substrates ; midazolam ( CYP3A4 ) , omeprazole ( CYP2C19 ) , tolbutamide ( CYP2C9 ) dextromethorphan ( CYP2D6 ) single dose chronic administration . IV . To assess influence polymorphism CYP3A4 , 3A5 , 2C9 , ABCB1 , 2D6 RO4929097 plasma pharmacokinetics V. To assess evidence clinical activity ( CR , PR , SD ) patient advance solid tumor . OUTLINE : Patients randomize 1 2 treatment regimen . Regimen I ( low-dose RO4929097 ) : Patients receive low-dose RO4929097 orally ( PO ) daily day 1-3 , 8-10 , 15-17 midazolam hydrochloride IV 1 minute , omeprazole PO , tolbutamide PO , dextromethorphan hydrobromide PO day 1 10 . After completion course 1 , patient randomize 1 2 treatment arm . Arm A : Patients receive low-dose RO4929097 PO daily day 1-3 , 8-10 , 15-17 ketoconazole PO daily day 1-10 course 2 . For course 3 beyond , patient receive low-dose RO4929097 day 1-3 , 8-10 , 15-17 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Arm B : Patients receive low-dose RO4929097 PO daily day 1-3 , 8-10 , 15-17 rifampin PO daily day 1-10 course 2 . For course 3 beyond , patient receive low-dose RO4929097 day 1-3 , 8-10 , 15-17 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Regimen II ( high-dose RO4929097 ) : Patients receive high-dose RO4929097 PO daily day 1-3 , 8-10 , 15-17 midazolam hydrochloride IV , oral omeprazole , oral tolbutamide , oral dextromethorphan hydrobromide day 1 10 . After completion course 1 , patient randomize 1 2 treatment arm . Arm A : Patients receive high-dose RO4929097 daily day 1-3 , 8-10 , 15-17 oral ketoconazole daily day 1-10 course 2 . Arm B : Patients receive high-dose RO4929097 daily day 1-3 , 8-10 , 15-17 oral rifampin daily day 1-10 course 2 . In arm , treatment RO4929097 repeat every 21 day &gt; = 3 course absence disease progression unacceptable toxicity . Patients undergo blood sample collection baseline periodically study pharmacokinetics study evaluation SNPs CYP2D6 , CYP2C9 , ABCB1 , CYP3A4/5 . After completion study therapy , patient follow 30 day .</detailed_description>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<mesh_term>Tolbutamide</mesh_term>
	<criteria>Patients must histologically confirm malignancy metastatic unresectable standard therapy Patients must receive radiation &gt; 25 % bone marrow ECOG performance status = &lt; 2 ( Karnofsky &gt; = 60 % ) Life expectancy great 12 week Hemoglobin &gt; = 9 g/dL Leukocytes &gt; = 3,000/mcL Absolute neutrophil count &gt; = 1,500/mcL Platelets &gt; = 100,000/mcL Total bilirubin within normal institutional limit AST ( SGOT ) /ALT ( SGPT ) = &lt; 2.5 X institutional upper limit normal Creatinine within normal institutional limit OR creatinine clearance &gt; = 60 mL/min/1.73 m^2 patient creatinine level institutional normal Preclinical study indicate RO4929097 substrate CYP3A4 inducer CYP3A4 enzyme activity ; caution exercise dose RO4929097 concurrently CYP3A4 substrate , inducer , and/or inhibitor ; furthermore , patient take concurrent medication strong inducers/inhibitors substrates CYP3A4 switch alternative medication minimize potential risk ; patient switch alternative medication , ineligible participate study Caution exercise dose ketoconazole , rifampin , omeprazole , midazolam , tolbutamide , dextromethorphan concurrently CYP3A4 substrate , inducer , and/or inhibitor ; furthermore , patient take concurrent medication strong inducers/inhibitors substrates CYP3A4 switch alternative medication minimize potential risk ; patient switch alternative medication , ineligible participate study The effect RO4929097on develop human fetus recommend therapeutic dose unknown ; reason Notch signal pathway inhibitor know teratogenic , woman childbearing potential men must use two form contraception ( i.e. , barrier contraception one method contraception ) least 4 week prior study entry , duration study participation , least 12 month posttreatment ; woman become pregnant suspect pregnant partner participate study 12 month study participation , patient inform treat physician immediately Women randomize Regimen I ( Arm B ) Regimen II ( Arm B ) , receive rifampin need use additional , nonhormonal birth control cycle 2 ; rifampin induces enzymes responsible hormone metabolism , make hormonal birth control ineffective ; woman become pregnant suspect pregnant participating study , inform treat physician immediately Ability understand willingness sign write informed consent document Patients must measurable disease , radiographically evaluable metastatic disease ( e.g . osseous metastasis ) evidence disease progression ( e.g . new lesion rise tumor marker ) Treated , stable brain metastasis allow ; patient must four week radiation stable brain imaging medication use treat brain metastasis , except antiepileptic metabolize cytochrome P450 Patients chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior enter study recover ( = &lt; grade 1 ) clinically significant adverse event due agent administer 4 week earlier ; prior palliative radiotherapy allow great 2 week elapse patient also recover baseline grade &lt; 1 treatment adverse effect Patients may receive investigational agent History allergic reaction attribute compound similar chemical biologic composition RO4929097 , agent use study Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , history torsades de pointes significant cardiac arrhythmia chronic , stable atrial fibrillation , psychiatric illness/social situation would limit compliance study requirement Pregnant woman exclude study RO4929097 gammasecretase inhibitor potential teratogenic abortifacient effect ; unknown potential risk adverse event nurse infant secondary treatment mother RO4929097 , breastfeed discontinue mother treated RO4929097 ; potential risk may also apply agent use study HIVpositive patient receive combination antiretroviral therapy ineligible potential pharmacokinetic interaction RO4929097 ; addition , patient increase risk lethal infection treat marrowsuppressive therapy ; appropriate study undertake patient receive combination antiretroviral therapy indicate Patients uncontrolled hypocalcemia , hypomagnesemia , hyponatremia , hypophosphatemia hypokalemia define less low limit normal institution , despite adequate electrolyte supplementation exclude study ; Note : acceptable use correct calcium interpret calcium level Patients must take omeprazole dextromethorphan , willing take study dose formulation PK day ; patient require likely require therapeutic dos drug exclude Patients must take rifampin , ketoconazole , tolbutamide , midazolam ; patient require likely require therapeutic dos drug exclude Patients must take monoamine oxidase inhibitor , Clorgyline , Iproniazid , Isocarboxazid , Moclobemide , Nialamide , Pargyline , Phenelzine , Procarbazine , Rasagiline , Selegiline , Teloxantrone , Tranylcypromine drug interaction dextromethorphan Patients must acute narrowangle glaucoma untreated openangle glaucoma , midazolam contraindicate Baseline QTcF &gt; 450 msec Patients serologically positive Hepatitis A , B C , history liver disease , form hepatitis cirrhosis ineligible Patients malabsorption syndrome condition would interfere intestinal absorption ; patient must able swallow tablet Because opioid contain pain medication may metabolize CYP3A4 pathway , patient monitor carefully avoid toxicity dos adjust necessary ; subject would tolerate adjustment opioid pain medication exclude Subjects history hypoglycemia , diabetes mellitus , abnormal glucagon regulation exclude ; subject current diagnosis diabetes mellitus receive treatment ( i.e . insulin medication ) eligible ; diagnosis diabetes mellitus manage diet allowable Subjects mild severe skin exanthems exclude A requirement antiarrhythmic medication know prolong QTc</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>